Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies in the United States, Europe, and internationally. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Its injection products also comprise Epinephrine Injection USP for treating Anaphylaxis; Makena auto injectors to reduce the risk of preterm birth in women pregnant with a single baby; ZOMAJET and Twin-Jector EZ II Needle-free Injectors to administer human growth hormone for patients with growth retardation. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; and QuickShot auto injectors. It has strategic alliances with Teva Pharmaceutical Industries, Ltd., AMAG Pharmaceuticals, Inc., Idorsia Pharmaceuticals Ltd, and Pfizer Inc. The company was founded in 1978 and is headquartered in Ewing, New Jersey. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
JACOB LEONARD S | Director | Feb 18 | Option Exercise | 2.24 | 15,321 | 34,319 | 268,363 | Feb 19 07:08 PM | GRAHAM PETER J | EVP General Counsel, Secretary | Feb 18 | Option Exercise | 1.12 | 45,000 | 50,400 | 585,417 | Feb 19 07:07 PM | APPLE ROBERT F | President & CEO | Feb 18 | Option Exercise | 0.88 | 250,000 | 220,000 | 2,696,720 | Feb 19 07:11 PM | APPLE ROBERT F | President & CEO | Feb 18 | Sale | 5.00 | 491,960 | 2,459,978 | 2,204,760 | Feb 19 07:11 PM | GRAHAM PETER J | EVP General Counsel, Secretary | Feb 18 | Sale | 4.93 | 45,000 | 221,650 | 540,417 | Feb 19 07:07 PM | JACOB LEONARD S | Director | Feb 18 | Sale | 5.05 | 15,321 | 77,371 | 253,042 | Feb 19 07:08 PM | APPLE ROBERT F | President & CEO | Feb 17 | Option Exercise | 2.62 | 5,519 | 14,460 | 2,452,239 | Feb 19 07:11 PM | APPLE ROBERT F | President & CEO | Feb 17 | Sale | 4.75 | 5,519 | 26,215 | 2,446,720 | Feb 19 07:11 PM | GARRITY THOMAS J | Director | Feb 11 | Option Exercise | 1.12 | 50,000 | 56,000 | 274,406 | Feb 12 06:53 PM | GARRITY THOMAS J | Director | Feb 11 | Sale | 4.62 | 50,000 | 231,000 | 224,406 | Feb 12 06:53 PM | APPLE ROBERT F | President & CEO | Feb 10 | Option Exercise | 2.62 | 7,278 | 19,068 | 2,302,433 | Feb 10 08:11 PM | APPLE ROBERT F | President & CEO | Feb 10 | Sale | 4.75 | 7,278 | 34,571 | 2,295,155 | Feb 10 08:11 PM | APPLE ROBERT F | President & CEO | Feb 09 | Option Exercise | 2.62 | 49,129 | 128,718 | 2,344,284 | Feb 10 08:11 PM | APPLE ROBERT F | President & CEO | Feb 09 | Sale | 4.75 | 49,129 | 233,363 | 2,295,155 | Feb 10 08:11 PM | APPLE ROBERT F | President & CEO | Feb 08 | Option Exercise | 2.62 | 33,574 | 87,964 | 2,328,729 | Feb 10 08:11 PM | APPLE ROBERT F | President & CEO | Feb 08 | Sale | 4.75 | 33,574 | 159,477 | 2,295,155 | Feb 10 08:11 PM | GARRITY THOMAS J | Director | Jan 11 | Option Exercise | 1.44 | 70,000 | 100,800 | 274,406 | Jan 13 08:21 PM | GARRITY THOMAS J | Director | Jan 11 | Sale | 4.06 | 70,000 | 283,900 | 224,406 | Jan 13 08:21 PM | Powell Fred M | Executive Vice President & CFO | Nov 12 | Buy | 2.85 | 16,400 | 46,740 | 646,465 | Nov 16 07:04 AM | GUETH ANTON | Director | May 13 | Option Exercise | 1.60 | 72,487 | 115,979 | 399,236 | May 15 04:30 PM |
|